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Background: Eosinophilic inflammation of the airways is a key characteristic of asthma. A
defect in eosinophil apoptosis might contribute to the chronic tissue eosinophilia
associated with asthma.
Objective: Our purpose was to examine whether the occurrence of apoptotic eosinophils in
induced sputum from asthmatic patients correlate with interleukin (IL)-5 and eotaxin.
Methods: Thirty stable and 30 exacerbated asthmatic patients were recruited. Twenty
healthy subjects were enrolled as a control group. Induced sputum was obtained from
asthmatic patients and from control subjects. The number of apoptotic eosinophils in
sputum was assessed by flow cytometry. In sputum supernatant, eosinophil cationic protein
(ECP) was measured by sensitive radioimmunoassay, and IL-5 and eotaxin by sandwich
enzyme linked immunosorbant assay.
Results: Levels of eosinophils, apoptotic eosinophils, IL-5, ECP and eotaxin from asthmatic
patients were higher than those from healthy subjects. Thirty exacerbated asthmatics
showed higher proportions of eosinophils (median 29.3%, range 13.4%–40.9%), more
detectable levels of IL-5 (50.44, 32.99–67.01pg/ml) and eotaxin (644.6, 197.4–937.7pg/ml) in
their sputum than the patients with stable asthma (Po0:05). There were significant
inverse correlations between the levels of sputum IL-5 and the proportion of sputum
eosinophil apoptosis in patients with exacerbated and stable asthma (r ¼ 0:85 and
0.79, Po0:01 and Po0:05, respectively). Also inverse correlations were found between
the levels of eotaxin and the proportion of sputum eosinophil apoptosis in exacerbated
(r ¼ 0:85, Po0:01), or stable asthma (r ¼ 0:69, Po0:05). Additional positive corrla-
tions between the levels of sputum IL-5 and eotaxin in either exacerbatated (r ¼ 0:93,
Po0:01) or stable asthma (r ¼ 0:82, Po0:05) were observed.Elsevier Ltd. All rights reserved.
224781; fax: +46 13 224764.
io.se (O. Zetterstro¨m).
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J. Xu et al.1448Conclusions: Apoptosis of eosinophils might be suppressed by proinflammatory cytokines
and chemokines such as IL-5 and eotaxin leading to their accumulation in the lung.
Stimulation of eosinophils in airway with IL-5 and eotaxin may play a crucial role in allergic
inflammation.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Eosinophils are known to play a pivotal role in asthmatic
airway inflammation. Infiltration of eosinophils into the
bronchial wall and respiratory epithelial damage are two
distinctive features of asthma.1 These bronchial changes
involve four steps—namely, enhanced eosinophil produc-
tion, recruitment to lung tissue, activation of eosinophils,
and release of mediators. The prolongation of eosinophil
survival is important in the pathogenesis of asthmatic airway
inflammation. Apoptosis plays a central part in normal tissue
homeostasis as well as having a role in various clinical
diseases characterized by either increased or decreased cell
survival.2 It is thought to be critically important in
promoting the clearance of inflammatory cells and the
resolution of inflammation. Apoptosis of eosinophils may be
clinically relevant in asthma, promoting the removal of
airway eosinophils and contributing to clinical improvement.
The recruitment of eosinophils to the airway is complex,
and involvement of a number of cytokine families has been
considered. Understanding the mechanisms of eosinophil
recruitment to the airway and the regulation of eosinophil
chemotaxis and activation can potentially lead to further
improvement in the treatment of asthma. Interleukin (IL)-5,
a cytokine that attracts, activates, and prolongs the survival
of eosinophils, is important in causing eosinophilic inflam-
mation in the asthmatic airway and contributes to eosinophil
viability in the sputum of asthmatic patients during attacks.3
Eotaxin is a chemokine with potent and selective chemo-
tactic activity for eosinophils.4 Recent studies have reported
increased eotaxin levels in the bronchial mucosa, broncho-
alveolar lavage fluid and sputum5,6 from asthmatic patients
compared with healthy subjects. These findings suggest that
besides IL-5, eotaxin may contribute to the pathogenesis of
asthma.
This study was designed to determine whether the
occurrence of eosinophil apoptosis in sputum reflects
activity in patients with asthma. The relationships between
number of eosinophils and percentage of eosinophil apop-
tosis in sputum and IL-5 and eotaxin in sputum supernatant
were evaluated.Methods
Subjects
Patients attending the respiratory outpatient clinic and
hospitalized patients at Fifth Affiliated Hospital of Zhong-
shan University were screened for the study. Thirty stable
and 30 exacerbated asthmatics were selected. All subjectswere 18 years or older and the diagnosis of asthma was
defined and assessed by means of the global initiative for
asthma (GINA) updated in 2002.7 The inclusion criteria
were: nonsmoking subjects with clinically exacerbated or
stable asthma; a documented reversibility415% of baseline
FEV1 following inhaled salbutamol 200 mg and a percentage
of eosinophils X7% in induced sputum. Sputum samples
containing more than 30% squamous cells were excluded
from the analysis. Patients had not received corticosteroids,
cromoglycate, theophylline, or other medications 6 weeks
before presentation, except for rescue inhaled b2-agonists.
Inhaled b2-agonists were withheld for 12 h before venipunc-
ture. No subject had any obvious respiratory infection for at
least 1 month prior to sputum collection.
A separate group of 20 healthy nonsmoking subjects
selected from a health-examination served as controls. They
had no evidence of allergic rhinitis, asthma as identified on
the basis of history or other allergic diseases. They had
normal total IgE levels and eosinophil counts in peripheral
blood. Spirometry was within normal limits in these
subjects.
All visits comprised a medical history, allergy skin tests,
baseline spirometry, sputum induction and hypertonic saline
challenge. All subjects gave their informed consent.Clinical assessment
Skin-prick tests were performed with commercial extracts
(Dome/Hollister-Steir, Bayer Pharmaceuticals, Sydney,
Australia) for house dust mites (Dermatophagoides ptero-
nyssinus and Dermatophagoides farinae), mold mix (Alter-
naria, Aspergillus mix, Hormodendrum, Penicillium mix),
mixed grasses, cat fur (cat hair and epithelium), and
cockroach, together with positive (histamine) and negative
(glycerine) controls. A skin-prick test was defined as positive
if the wheal diameter was 3mm or greater at 15min. A
subject was considered atopic if a positive skin-prick test
was recorded for any allergen. Spirometry was performed on
Microspiro-HI 298, Chest (Tokyo, Japan) and the best of
three FEV1 and FEF25–75 percentage of predicted maneuvers
were recorded. The specialist was asked to classify patients
into one of the four severity categories based on a
combination of symptoms and FEV1 criteria and according
to the GINA recommendations.7Sputum induction and processing
Sputum was induced with an aerosol of hypertonic saline
using a slight modification of the method described by
Pizzichini et al.8 Inhaled salbutamol at 200 mg was given via
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Hypertonic saline (3%, 4% and 5%), generated by an
ultrasonic nebulizer (Ultraneb 2000; DeVilbiss, Somerset,
PA, USA), was inhaled at each concentration for 7min. The
output of the nebulizer was calibrated at 2.5ml/min. At the
start and after each period of inhalation, FEV1 was measured
for safety reasons. After inhalation of the hypertonic saline,
subjects were asked to blow their nose, rinse their mouth,
and swallow water to minimize contamination from post-
nasal drip and saliva. The subjects were then instructed to
cough sputum into a sterile container.
The samples of sputum were then gently mixed using a
vortex mixer and placed in a shaking water bath at 37 1C for
15min to ensure complete homogenization. The resulting
suspension was filtered through 48 mm nylon gauze. The
filtrate was centrifuged at 2000 g for 4min, to separate
the supernatant from the cell pellet. The supernatants were
aspirated and stored in Eppendorf tubes at 70 1C in
separate aliquots for later assay. During examination, the
volume of the entire supernatant was measured and divided
into two aliquots. One volume of 0.1% dithiothreitol (DTT)
(Sputolysin 10%; Calbiochem Corp., San Diego, CA, USA) for
IL-5 and ECP detecting assays and four volumes of PBS for
eotaxin test were added to per volume of sputum.
The cell pellet was adjusted to 1.0 106/ml, and
cytocentrifuge preparations were made using 60 ml of cell
suspension (Shandon III cytocentrifuge; Shandon Southern
Instruments, Sewickley, PA, USA). The slides were stained
with May–Grunwald–Giemsa stain, and different cell counts
in sputum were determined by at least 400 differential non-
squamous cells, using standard haemocytologic procedures.
Results were expressed as a percentage of the total
nonsquamous cell count. A person blinded to the clinical
characteristics of the subjects performed the sputum
measurements.
Eosinophil isolation
The sputum pellet was resuspended in 10ml of saline in a 50-
ml tube. Ten milliliters of Percoll working solution (9ml of
Percoll; Sigma P1644; 1ml 10Dulbeccos phosphate buf-
fered saline (DPBS) without calcium/magnesium; saline
adjusted to 1.079 g/ml) was layered underneath the cell
suspension and the tube was centrifuged at 400 g for
30min at room temperature. The top layers, including the
mononuclear cell-containing interface, were aspirated and
the pellet, containing mostly eosinophils. Contaminating red
blood cells were lysed by cold milli-Q water for 5–10 s. One
milliliter of 10DPBS was immediately added and cells
were pelleted at 300 g. Cells were then washed with 10ml
of DPBS. The cells were suspended in 10% fetal calf serum-
containing RPMI 1640 solution. In all cases, cells were495%
in terms of both viability and eosinophil purity. Cell viability
was determined by trypan blue exclusion. Eosinophil purity
was assessed by Wright–Giemsa stained cytospins.
Assessment of eosinophil apoptosis
After 3 days of incubation at 37 1C in a 5% CO2-containing
incubator, cells were harvested and the differential analysis
of apoptotic cells was performed by the analysis of annexinV binding and propidium iodide (PI) uptake. Cells were
incubated (4 105 cells per tube) for 15min at room
temperature in 100 ml containing 5ml annexin V FITC and
10 ml PI (Bender medSystem GmbH Rennweg, Vienna,
Austria) in the dark with agitation. Two hundred microliters
of the sample was diluted to 500 ml with binding buffer just
before flow analysis. Samples were analyzed with a FACScan
(Becton–Dickinson, San Jose, CA) and CellQuest cell analysis
software (Becton–Dickinson). Forward angle light scatter
and side scatter were used to gate the eosinophil population
to include changes in light scatter properties accompanying
the onset of apoptosis and exclude debris. At each time
point, an unlabeled control also was prepared to ensure that
observed fluorescence was not due to any changes in
autofluorescence. Color compensation was set to eliminate
FITC spill into the FL2 detector and PI spill into the FL1
detector. Green (Annexin V FITC) versus red (PI) fluores-
cence was assessed to monitor onset of apoptosis. Analysis
was accomplished by use of quadrant stats in CellQuest
software. Quadrants were set so that cells in lower left (LL)
quadrant were viable cells (unlabeled). Non-viable (dead)
cells (UL) will be PI positive, FITC positive cells were
indicative of early apoptosis (LR), and FITC/PI positive cells
indicated late apoptosis (UR). Total FITC positive (LRþ UR)
was used for comparative quantitation and graphing of
apoptosis among groups.Measurements of eotaxin, IL-5 and eosinophil
cationic protein levels in sputum
The levels of eotaxin and IL-5 in sputum supernatant were
measured using enzyme immunoassays according to the
manufacturer’s protocol (R&D Systems, Minneapolis, Minn.,
and Endogen, Inc., Woburn, MA, respectively). The level of
eosinophils cationic protein (ECP) in sputum was measured
using a sensitive radioimmunoassay (Kabi Pharmacia Diag-
nostics, Uppsala, Sweden). Sensitivities for eotaxin, IL-5 and
ECP were 5, 5 and 2 pg/ml, respectively.Statistical analysis
Data are expressed as means7SEM or as median values, with
a range from the minimal to the maximal values. When the
variables showed normal distribution, the comparison was
performed using one-way analysis of variance and Student’s
t test. When the variables did not show normal distribution,
they were compared using the Kruskal–Wallis test. The level
of significance was set at Po0:05.Results
The age and gender were similar in each of the three groups.
FEV1 and FEF25–75 (percentage of predicted) were both
significantly lower, and the levels of IgE and eosinophils in
blood were significantly higher in asthmatic patients than in
healthy subjects, and FEV1 and FEF25–75 (percentage of
predicted) were much lower in exacerbated asthmatics than
in stable ones (Table 1).
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Table 1 Subject and sputum characteristics and ECP levels in the study.
Characteristics Control group (n ¼ 20) Stable group (n ¼ 30) Exacerbated group (n ¼ 30)
Age (year) 47.5 (18–64) 48.5 (19–65) 45.5 (20–65)
Sex (M/F) 9/11 16/14 13/17
Allergic rhinitis, n (%) 0 17 (57) 17 (57)
Serum IgE (IU/ml) 133.4743.4 304.3797.3** 534.17276.3**#
Blood eosinophils (/ml) 151754 301791* 3417117**
Atopy, n (%) 4 (20) 24 (80) 25 (83)
FEV1, % predicted 92.178.4 77.5710.7** 71.0710.9**
#
FEF2575, % predicted 88.478.4 73.5711.0** 64.6710.7**
##
Sputum indices
Total cell count,  106/g 0.99 (0.19–2.99) 1.56 (0.18–5.02) 1.65 (0.28–5.78)
Eosinophils (%) 2.4 (0.2–3.7) 20.3 (8.3–44.4)** 29.3 (13.4–40.9)**#
Macrophages (%) 70.9 (36.1–92.2) 54.9 (30.3–82.8)* 49.4 (28.9–83.2)*
Neutrophils (%) 16.2 (4.2–40.8) 16.1 (3.9–44.3) 14.5 (3.6–42.9)
Lymphocytes (%) 4.5 (0.3–14.2) 3.6 (0.2–8.6) 2.1 (0.5–8.8)*
Epithelial cells (%) 7.2 (0.8–21.5) 6.9 (1.2–19.4) 3.9 (1.4–22.2)*
ECP (ng/ml) 109.6 (19.5–302.5) 4992.2 (759.6–8763.7)** 5014.9 (143.4–9938.1)**
Data are presented as mean7SEM or shown as median (range).
*Po0.05, **Po0.01, compared with control. #Po 0.05, compared with stable group.
J. Xu et al.1450Characteristics of the sputum
All subjects tolerated the sputum induction procedure well
and sputum could be obtained from all 20 healthy subjects
and all patients with asthma. Table 1 shows the results of
cytological analyses and ECP levels in sputum. The median
numbers of total cells and proportions of neutrophils in
sputum did not differ significantly between the three
groups. The median proportions of lymphocytes and epithe-
lial cells were significantly lower in asthmatic patients with
exacerbation (2.1% and 3.9%, respectively) than in the
healthy subjects (4.5% and 7.2%, respectively) (Po0:05).
The study showed that proportions of eosinophils in sputum
were much higher both in exacerbated and in stable
asthmatic patients (29.3%, 20.3%) than in healthy subjects
(2.4%, Po0:01). In exacerbated asthmatics, the median
percentage of eosinophils in sputum (29.3%) was signifi-
cantly higher than in the stable asthmatic patients
(20.3%, Po0:05). The median concentrations of ECP in
sputum supernatant were much higher in patients both
with exacerbated (5014.9 ng/ml) and stable asthma
(5092.4 ng/ml) than in the healthy subjects (109.6 ng/ml,
Po0:01).IL-5, eotaxin and apoptotic eosinophil levels in
sputum
IL-5, eotaxin and apoptotic eosinophils could not be
detected in sputum supernatant from two of the healthy
subjects. Hence, the results are given for 18 healthy
subjects. The median levels of IL-5 in sputum were 50.44
(range 32.99–67.01), 39.29 (22.37–64.55) and 10.46
(7.94–17.47) pg/ml in exacerbated and stable asthmatic
patients and healthy subjects, respectively (Fig. 1). More IL-
5 was found in asthmatic patients with exacerbation than in
the stable asthmatic patients (Po0:05). Even in the stableasthmatics, the level of IL-5 was significantly higher than in
healthy subjects (Po0:01).
The median levels of eotaxin in sputum were 644.6 (range
197.4–937.7), 342.2 (89.6–779.4) and 95.0 (10.2–384.9) pg/ml
in exacerbated and stable asthmatics and healthy subjects,
respectively (Fig. 1). The level of eotaxin was significantly
higher in both asthmatic patient groups compared to the
healthy subjects (Po0:01). More eotaxin was found in
the patients with exacerbated asthma than in those with
stable asthma (Po0:05).
The median for the proportions of apoptotic eosinophils in
sputum was 3.86 (range 2.04–5.98)% in exacerbated asth-
matics, 3.72 (2.11–5.86)% in stable asthmatics and 1.04
(0.79–2.13)% in the healthy subjects (Fig. 1). Thus, in both
groups of asthmatic patients, the proportion of apoptotic
eosinophils was significantly higher than in the healthy
subjects (Po0:01). The proportions of apoptotic eosino-
phils in sputum were similar in stable and exacerbated
asthmatics.
Correlations between IL-5, eotaxin, ECP, apoptotic
eosinophils, eosinophils in sputum and clinical
findings in stable and exacerbated asthmatic
patients
There were significant positive correlations between the
levels of IL-5, eotaxin and ECP in sputum supernatant and
the percentages of sputum eosinophils both in exacerbated
and stable asthmatic patients. No correlations were noted in
the patients with asthma between the proportions of
eosinophils in sputum and either IgE in blood or lung
function measurements (Table 2, Fig. 2).
In both the exacerbated and stable asthmatic patient
groups, the levels of sputum IL-5, eotaxin and ECP in sputum
supernatant were inversely correlated to the proportion of
sputum eosinophil apoptosis (Table 2, Fig. 2). There was no
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Figure 1 Levels of IL-5, eotaxin and proportions of eosinophil apoptosis in sputum obtained from exacerbated (A, n ¼ 30) and stable
(B, n ¼ 30) asthmatic patients, and healthy subjects (C, n ¼ 18). Horizontal bars represent median values. **Po0.01; #Po0.05.
Table 2 Correlations between percentage of eosinophils, and proportion of apoptotic eosinophils and the concentrations of
IL-5, eotaxin and ECP in sputum, and lung function changes in asthmatics irrespective healthy subjects.
IL-5 Eotaxin ECP IgE FEV1 FEF25–75
Eosinophils (exacerbated asthma) 0.94** 0.93** 0.80** NS NS NS
Eosinophils (stable asthma) 0.92** 0.79* 0.76* NS NS NS
Apoptotic eosinophils (exacerbated asthma) –0.85** –0.85** –0.74* NS NS NS
Apoptotic eosinophils (stable asthma) 0.79* –0.69* –0.75* NS NS NS
Data showed *Po0.05, **Po0.01.
NS: not significant.
Apoptotic eosinophils in sputum from asthmatic patients 1451correlation between the amounts of IgE in blood or lung
function parameters, and the percentage of apoptotic
eosinophils in sputum in the asthmatic patients.
The levels of sputum IL-5 in both stable and exacerbated
asthmatics were positively correlated with the concentra-
tion of sputum eotaxin (Fig. 3).
There were no correlations between the proportions of
eosinophils and of apoptotic eosinophils in sputum in stable
and exacerbated asthmatics.Discussion
Allergy is characterized by the accumulation of activated
eosinophils at the site of inflammation. Inhibition of
eosinophil apoptosis has been proposed as a key mechanism
for the development of tissue eosinophilia in allergic
disorders.9 IL-5, IL-3, and GM-CSF derived cytokines,
dramatically increase the life span of purified eosinophils
by inhibiting their spontaneous apoptosis in vitro.10,11
Moreover, these cytokines are overexpressed in inflamed
allergic tissue and have been shown to increase eosinophil
survival in vivo, thereby contributing to the accumulation of
eosinophils in allergic inflammation.12,13 In this study, we
have shown that exacerbated and stable asthmatics, in
comparison to healthy subjects, had significantly higherproportions of eosinophils both in blood and sputum, higher
proportions of apoptotic eosinophils in sputum, and higher
levels of IL-5, eotaxin and ECP in induced sputum. These
findings do not support the notion that decreased apoptosis
is a cause of eosinophil accumulation.
Asthma results from complex interactions between
inflammatory cells, mediators, and the cells and tissues of
the airways.14 Eosinophils are known to play a major part in
asthmatic airway inflammation. Recruitment from the blood
to the airway initially involves adherence of eosinophils to
endothelial cells and subsequent migration into an inflam-
matory site.15 In agreement with this concept, we also found
that eosinophil percentages in peripheral blood and induced
sputum were elevated in stable and exacerbated asthmatic
patients in comparison to healthy subjects. IL-5 enhances
the interaction between inflammatory cells and epithelial
cells.16 In lung tissue release of ECP is fundamental to the
proinflammatory role of eosinophils.17 We found that the
eosinophil activation markers IL-5 and ECP were significantly
increased in patients with stable and exacerbated asthma,
and the levels both of sputum IL-5 and ECP correlated
positively with the proportions of eosinophils in sputum in all
asthmatics. This suggests that the higher percentage of
eosinophils and increased levels of eosinophil activation
markers in asthmatic sputum are due to recruitment of
eosinophils and possibly degranulation of eosinophils in the
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J. Xu et al.1452bronchi. IL-5, a cytokine that attracts, activates and
prolongs the survival of eosinophils, is an important
eosinophil-regulating cytokine in the pathogenesis of aller-
gic inflammation and asthma, and its concentration in
asthmatics correlates with markers of eosinophil activation
and number of T lymphocyte.18 It also indicates that ECP is
fundamental to the proinflammatory role of eosinophils.
In this study, the proportions of apoptotic eosinophils in the
induced sputum were higher in stable and exacerbated
asthmatics, which may indicate that apoptotic eosinophilsare involved in allergic inflammation. Apoptosis or pro-
grammed cell death is an ordered process of fundamental
biological importance which is as vital to homeostasis as are
cellular proliferation, differentiation, and migration.19 It is
thought to be critically important in promoting the clearance
of inflammatory cells and the resolution of inflammation.
Apoptosis of eosinophils may be clinically relevant in asthma,
promoting the removal of airway eosinophils and contributing
to clinical improvement. IL-5 has an inhibitory effect on
eosinophil apoptosis by regulating bcl-2 expression.20 Dewson
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abrogating apoptosis. We found that IL-5 concentration in
sputum from asthmatic patients was negatively correlated to
the proportion of eosinophil apoptosis, which also suggests
that IL-5 inhibits the apoptosis of eosinophils. Since inap-
propriate accumulation of eosinophils and the subsequent
release of their potent armoury of mediators, including
cytotoxic granule proteins, lipid mediators, cytokines and
chemokines, are thought to contribute significantly to the
airway inflammation underlying asthma pathogenesis, pro-
grammed cell death (apoptosis) is probably important to avoid
excessive damage.22 The findings of an increased proportion
of apoptotic eosinophils in sputum from our asthmatic
patients seem to indicate a mechanism for the resolution of
an asthma attack. Whether individual asthmatic patients with
low levels of apoptotic eosinophils have a worse prognosis
remains to be seen.
Eotaxin production is regulated by and produced by cells
in the bronchi and may be important in the pathogenesis of
asthma and has been reported to play a role in eosinophilic
inflammation.23,24 Eotaxin mRNA is highly expressed in
sputum cells25 from asthmatic patients. Thus chemokine
networks seem to exist in eosinophilic inflammation. Our
results revealed that sputum obtained from asthmatic
patients showed detectable levels of eotaxin, and the
concentration of eotaxin was high compared to healthy
subjects. Sputum eotaxin correlated inversely with the
proportion of apoptotic eosinophils in sputum, and positively
with sputum eosinophils, indicating an important role for
eotaxin in eosinophil accumulation. Therefore, increased
inflammation may affect IL-5 (cytokine) and eotaxin
(chemokine) expression, suggesting that not only IL-5 but
also eotaxin, which acts as a hematopoietic rather than as a
chemoattractant factor, play important roles in eosinophil
accumulation in the airways.
Seton et al.26 reported that stimulus-dependent release
of the granule protein ECP was increased in apoptotic
eosinophils and hypothesized that the cytoskeleton of
eosinophils is disrupted during the apoptotic process. Their
results showed an increased propensity to release ECP in
response to appropriate stimuli. This study demonstrated
that in sputum there was a negative correlation between
apoptotic eosinophis and ECP in stable and exacerbated
asthmatics. We postulate that increasing ECP released from
both eosinophils and apoptotic eosinophils reaches an upper
critical level and inversely inhibits the propensity to
eosinophil apoptosis in asthma patients.
Our results revealed a positive correlation between
sputum IL-5 and sputum eotaxin obtained from exacerbated
and stable asthmatics. Exacerbated asthmatic patients
showed more elevated levels of IL-5 and eotaxin in sputum
than patients with stable asthma. This indicates that IL-5
and eotaxin could play a part in activation of asthma and
participate in the process of allergic inflammation although
possibly through different mechanisms. There were no
correlations between eosinophils or apoptotic eosinophils
in sputum and FEV1 and FEF25–75 (percentage of predicted)
in asthmatic patients. This finding suggests that eosinophils
and apoptotic eosinophils are not markers of clinical
severity in asthma.
In conclusion, this study showed elevated concentrations
of IL-5 and eotaxin, and high proportions of apoptoticeosinophils and eosinophils in sputum from asthmatic
patients. IL-5 and eotaxin in induced sputum also showed
positive correlation to the proportion of eosinophils, and
negative correlation to the percentage of eosinophil
apoptosis. These findings suggest that caution should be
applied when interpreting the presence of IL-5 and eotaxin
as specific markers for eosinophilic airway inflammation.
IL-5 and eotaxin enhance eosinophil numbers possibly by
influencing the apoptotic process of eosinophils in patients
with acute and stable asthma.Acknowledgment
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